Procter & Gamble Health Limited (NSE:PGHL) disclosed its unaudited financial results for the quarter ended June 30, 2026, via a press release filed with BSE and NSE on August 6, 2026. The company reported sales of Rs 356 crore and a reported PAT of Rs 96 crore for the period.
Key Highlights
- Consolidated sales for Q1 FY27 (quarter ended June 30, 2026) reached Rs 356 crore, a 7% increase compared to the same quarter a year ago.
- Reported Profit After Tax stood at Rs 96 crore, up 45% year-on-year, partly aided by one-time proceeds from the sale of an immovable asset.
- Operational PAT, which excludes the one-time asset-sale proceeds, was Rs 72 crore, reflecting 9% year-on-year growth on an underlying basis.
- Managing Director Milind Thatte attributed the performance to science-backed innovations, new consumer communication initiatives, and strengthened go-to-market capabilities.
About the Company
Procter & Gamble Health Limited (NSE:PGHL), headquartered in Mumbai, is one of India's largest vitamins, minerals, and supplements (VMS) companies. The company manufactures and markets brands including Neurobion, Livogen, SevenSeas, Evion, Polybion, and Nasivion, catering to consumer health and nutritional needs across India. It operates within the Pharma and Healthcare sector and is listed on both BSE (scrip code 500126) and NSE under the ticker PGHL.
Announcement in Detail
According to the press release approved at the Board of Directors meeting held on August 6, 2026, Procter & Gamble Health Limited delivered sales of Rs 356 crore for Q1 FY27, representing a 7% increase over the corresponding quarter of the prior year. The company attributed this top-line performance to strong brand fundamentals, superior retail execution, and positive consumer response to new product innovations introduced during the period.
Reported PAT for the quarter was Rs 96 crore, up 45% year-on-year. The filing explicitly states that this reported figure includes one-time proceeds from the sale of an immovable asset. Excluding those one-time proceeds, the company's Operational PAT was Rs 72 crore, which represents a 9% increase over the prior-year quarter, reflecting underlying business growth driven by supply chain and go-to-market improvements.
Impact on Investors
Investors will note that the 45% reported PAT growth includes a one-time gain from the sale of an immovable asset, which the company has separately disclosed. The filing shows that Operational PAT, the figure that strips out this non-recurring item, grew at a more moderate 9% year-on-year to Rs 72 crore. Shareholders will observe that this distinction is material when assessing the sustainability of the earnings trajectory beyond Q1 FY27.
The disclosed terms indicate that sales growth of 7% was supported by both distribution and innovation efforts rather than pricing alone, which the filing attributes to strengthened supply chain and go-to-market capabilities. No dividend declaration or other corporate action was announced alongside these results, based on the exchange filing reviewed.
Sector / Market Context
India's vitamins, minerals, and supplements market has seen consistent volume expansion in recent years, supported by rising preventive healthcare awareness. According to FICCI and industry data, India's consumer health segment, which includes OTC nutrition brands, has been among the faster-growing sub-segments within the broader pharmaceutical market, providing an operational context for P&G Health's continued focus on its VMS-led brand portfolio.